CORRESP Filing
Calidi Biotherapeutics, Inc.
Date: July 24, 2025 · CIK: 0001855485 · Accession: 0001641172-25-020815
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288784
Letter
Calidi Biotherapeutics, Inc.
Executive Drive, Suite 200
San Diego, CA 92121
(858) 794-9600
July 24, 2025
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street N.E.
Washington, D.C. 20549
Re: Calidi Biotherapeutics, Inc.
Registration Statement on Form S-3
File No. 333-288784
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time on Friday, July 25, 2025, or as soon thereafter as practicable.
Please contact Marcelle Balcombe, of Sichenzia Ross Ference Carmel LLP at (212) 930-9700, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Very
truly yours,
CALIDI
BIOTHERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Calidi Biotherapeutics, Inc. 4475 Executive Drive, Suite 200 San Diego, CA 92121 (858) 794-9600 July 24, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Calidi Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-288784 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time on Friday, July 25, 2025, or as soon thereafter as practicable. Please contact Marcelle Balcombe, of Sichenzia Ross Ference Carmel LLP at (212) 930-9700, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. Very truly yours, CALIDI BIOTHERAPEUTICS, INC. By: /s/ Andrew Jackson Andrew Jackson Chief Financial Officer